Global HbA1c testing device (Hemoglobin A1c) market is expected to reach USD 2.20 billion by 2021, growing at a CAGR of 11 % between 2016 and 2021.
The report covers forecast and analysis for the HbA1c testing device market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based on revenue (USD Billion). The study includes drivers and restraints for the HbA1c testing device market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the HbA1c testing device market on a global level.
This report offers comprehensive coverage on global HbA1c testing device market along with, market trends, drivers, and restraints of the HbA1c testing device market. This report includes a detailed competitive scenario and technology portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter’s five forces model for the HbA1c testing device market has also been included. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness. This report is prepared by using data sourced from in-house databases, secondary and primary research team of industry experts. Research analysts and consultants cooperate with leading companies of the concerned domain to verify every value of data exists in this report.
The study provides a decisive view on the HbA1c testing device market by segmenting the market based on device type, technology type, end user, and regions. All these segments have been analyzed based on present and future trends and the market is estimated from 2015 to 2021. The device type market covered under this study includes handheld device and bench-top device. The technology type based market covered under this study includes ion-exchange HPLC, enzymatic assay, affinity binding chromatography, turbidimetric inhibition immunoassay and other. The end user type market covered under this study includes hospitals, homecare, diagnostic laboratory and research institution. This report also includes the current and forecast demand for the region of North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa.
Key operating players in HbA1c testing device market are like Transasia Biomedicals ltd., Abbott Laboratories, Alere, Inc., Arkray, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare and Trinity Biotech plc.
This report segments the HbA1c testing device market as follows:
HbA1c Testing Device Market: Device Type Analysis
HbA1c Testing Device Market: Technology Type Analysis
HbA1c Testing Device Market: Device Type Analysis
HbA1c Testing Device Market: Regional Type Analysis
This report is based on in-depth qualitative and quantitative analyses of the global Hba1c Testing Device Market market. Zion Research has collected and analyzed key data belong to the global Hba1c Testing Device Market market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.
The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.
Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Hba1c Testing Device Market across the world has been calculated through primary and secondary research.
Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc.
For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in the validation of findings from secondary research and to understand key trends in the Hba1c Testing Device Market industry. Primary research makes up the major source of data collection and validation.
We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:
Participants who typically participate in such a process include, but are not limited to:
Key opinion leaders specializing in different areas corresponding to different industry verticals
Secondary research sources that are typically referred to include, but are not limited to:
News articles, press releases and webcasts specific to companies operating in the market
Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Hba1c Testing Device Market market.
Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:
Hemoglobin is the iron containing and oxygen transporting metalloprotein found in the red blood cells of vertebrates. HbA1c is a form of hemoglobin to which glucose binds in the red blood cells and it is also referred as glycated hemoglobin. Diabetes mellitus is a metabolic disorder characterized by disturbances of carbohydrate and chronic hyperglycemia resulting from defects in insulin secretion. The long–term effects of diabetes mellitus include the development of nephropathy, neuropathy, and retinopathy. People with diabetes mellitus are also at a risk of cerebrovascular disease, peripheral arterial, and cardiac diseases. HbA1c is an ideal marker for diabetes monitoring and diagnosis. HbA1c molecule reflects average glucose level over the previous eight to 12 weeks.
The increasing prevalence of raised blood sugar or hyperglycemia is a common effect of uncontrolled diabetes mellitus and it has affected around 422 million people in 2014. This global prevalence of diabetes has increased by 8.5% in 2014. Thus, the market for HbA1c testing device is propelled by rising diabetic adult population and rising prevalence of diabetes in middle and low-income countries. Moreover, HbA1c testing device market is rapidly growing due to rising awareness preventive care and diabetes management. Diabetes has emerged as one of the most challenging public health problems and it is a major cause of stroke, blindness, heart attacks and kidney failure. Thus, diabetic patient education becomes a prime component of diabetes management. In addition, technological advancement in HbA1c measurement is continuously responsible for the growth of HbA1c testing device market. Recently, HbA1c testing has been incorporated into point of care devices. However, the cost of the device and low diagnostic performance of test in pregnancy, elderly and non-Hispanic black population may hamper the growth of HbA1c testing device market. Nonetheless, untapped market and rapidly rising use of the HbA1c test for diabetes management are projected to generate opportunity in the forecast period.
Based on the device type, the market of the HbA1c testing device has been bifurcated into the handheld device and bench-top device. In 2015, bench-top device segment dominated the market for HbA1c testing device with major market share. In the forecast period, handheld device segment is expected to exhibit noticeable growth due to rising awareness of personal care.
Technology type segment has been further classified into ion-exchange HPLC, enzymatic assay, affinity binding chromatography, turbidimetric inhibition immunoassay and other. In 2015, affinity binding chromatography segment dominated the HbA1c testing device market and the dominance of affinity binding chromatography is due to widely use of technology in device manufacturing. As a result of this, it is expected to generate new opportunities in the forecast period. Affinity binding chromatography technology uses the principle of affinity and high-performance liquid chromatography (HPLC). Affinity binding chromatography requires no sample pretreatment to remove the labile.
Based on the end user type, the HbA1c testing device market is classified into hospitals, homecare, research institutions and diagnostic laboratory. The diagnostic laboratory was the largest segment in 2015 and it is expected to show significant growth in the forecast period.
Based on the regional, the HbA1c testing device market is classified into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America dominated the HbA1c testing device market in 2015 with around 40% market share. North America HbA1c testing device market was driven by well-developed healthcare infrastructure and rising prevalence of diabetes mellitus. Europe and Asia Pacific market are projected to show healthy growth in coming years.
Key operating players in HbA1c testing device market include Transasia Biomedicals Ltd., Abbott Laboratories, Alere, Inc., Arkray, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare and Trinity Biotech plc.